A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

Conditions: Advanced or Metastatic Breast Cancer Interventions: Drug: PF-07220060; Drug: Fulvestrant; Drug: Everolimus; Drug: Exemestane Sponsors: Pfizer Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials